文献速递淋巴瘤

美国复发/难治性弥漫大B细胞淋巴瘤患者CAR-T细胞治疗可及性的不平等:SEER-Medicare数据分析

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis.
PubMed 文献 · Blood Adv · 2025-01-01

本研究利用2007至2020年SEER-Medicare数据,评估接受三线及以上治疗的弥漫大B细胞淋巴瘤(DLBCL)Medicare患者中CAR-T细胞治疗的使用情况及可及性差异。2017至2020年间共2241例患者接受三线及以上治疗,其中122例(5.4%)接受CAR-T治疗;CAR-T接受者合并多种共病可能性较低(OR 0.904,P=.001),居住于较高收入地区可能性较高(OR 1.176,P=.004)。若「可及性差」州到最近授权治疗中心的平均距离由104.4英里降至「可及性较好」州的34.2英里,接受CAR-T治疗的患者数将增加37.6%(6.6%-9.1%,P<.001)。

要点

  • 2017至2020年2241例三线及以上DLBCL患者中122例(5.4%)接受CAR-T治疗。
  • CAR-T接受者合并多种共病可能性较低(OR 0.904,P=.001),居住于较高收入地区可能性较高(OR 1.176,P=.004)。
  • 「可及性差」州到最近授权治疗中心的平均距离由104.4英里降至34.2英里时,接受CAR-T治疗患者数将增加37.6%(6.6%-9.1%,P<.001)。

核心结论

  • 研究显示CAR-T细胞治疗在Medicare的DLBCL患者中存在因地理和社会经济因素导致的显著使用差异。
  • 作者认为解决这些障碍可显著改善CAR-T治疗的可及性并改善医疗服务不足人群的结局,强调需要针对性干预以减少地理和系统性照护障碍。

研究设计与样本

  • 基于2007至2020年SEER-Medicare数据的分析,采用多变量logistic回归评估患者特征及到授权治疗中心距离对CAR-T可及性的影响。
  • 2017至2020年间共2241例患者接受三线及以上DLBCL治疗,其中122例(5.4%)接受CAR-T治疗。

主要发现

  • CAR-T接受者合并多种共病的可能性较低(OR 0.904,P=.001)。
  • CAR-T接受者居住于较高收入地区的可能性较高(OR 1.176,P=.004)。
  • 若「可及性差」州(到授权治疗中心平均距离104.4英里)的距离降至「可及性较好」州的平均距离34.2英里,接受CAR-T治疗的患者数将增加37.6%(6.6%-9.1%,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has shown curative potential for patients with diffuse large B-cell lymphoma (DLBCL) and other malignancies, but its accessibility among Medicare patients, particularly in disadvantaged populations, remains uncertain. This study aims to assess CAR-T use among Medicare patients with DLBCL receiving third-line or later (3L+) treatment, focusing on access disparities and their impact on clinical outcomes. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2007 to 2020, multivariate logistic regression was used to evaluate patient characteristics and the effects of distance to authorized treatment centers (ATCs) on CAR-T access. Between 2017 and 2020, 2241 patients were treated for 3L+ DLBCL in the SEER-Medicare data, of whom 122 (5.4%) received CAR-Ts. CAR-T recipients were less likely to have multiple comorbidities (odds ratio [OR], 0.904; P = .001) but more likely to live in higher income areas (OR, 1.176; P = .004). If distance to the nearest ATC for "poor-access" states (average distance to ATC, 104.4 miles) decreased to the average distance in "better-access" states (34.2 miles), there would be a 37.6% increase in number of patients receiving CAR-Ts (6.6%-9.1%; P < .001). These findings highlight substantial disparities in CAR-T use, driven by geographic and socioeconomic factors. Addressing these barriers could significantly enhance equitable access to CAR-T therapy and improve outcomes for underserved populations, emphasizing the need for targeted interventions to reduce geographic and systemic barriers to care.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chung AP, Shafrin JT, Vadgama S, et al. Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis. Blood Adv. 2025. PMID: 40378343. doi:10.1182/bloodadvances.2024015634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。